The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 600 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 1 Oct 2030
- Type of study
- Interventional, 4 groups
- Treatments tested
- Live attenuated influenza vaccine
- Placebo nasal spray
- recombinant hemagglutinin influenza vaccine
- Placebo injection
- Record updated
- 15 May 2026
Who can take part
- Age
- 22 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged 22-50 years at enrolment
- A. Participated in the DRIVE I or DRIVE II studies (for DRIVE IIIa). OR B. Did not participate in the DRIVE I or DRIVE II study (for DRIVE IIIb) and has not received influenza vaccination in the prior two years
- Capable of providing informed consent
- Resident in Hong Kong in the coming 2 years
Who cannot take part
- Currently taking medication for any condition that impairs immune system
- Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
- Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition ), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry)
- With diagnosed medical conditions related to their immune system
- Individuals who report medical conditions not suitable to receive live attenuated vaccines, such as:; having asthma; having close contact with severely immunosuppressed persons who require a protected environment; or; having immunosuppressive treatment (e.g. high-dose steroid, anti-cancer drugs and radiotherapy)
- Individuals who report medical conditions not suitable to receive intramuscular injection, such as; Bleeding disorders; Habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
- Individuals who have any medical conditions not suitable to receive inactivated or live attenuated influenza vaccines as determined by a clinician
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness.
The 4 groups in the trial
- Arm 1: 4 x FluMistTreatment being tested
FluMist four times annually
Treatment: Live attenuated influenza vaccine and Placebo injection
- Arm 2: alternate FluMist and FlublokTreatment being tested
Alternating FluMist and Flublok annually
Treatment: Live attenuated influenza vaccine, Placebo nasal spray, recombinant hemagglutinin influenza vaccine, and Placebo injection
- Arm 3: alternating Placebo and FlublokTreatment being tested
Alternating Placebo and Flublok annually
Treatment: Placebo nasal spray, recombinant hemagglutinin influenza vaccine, and Placebo injection
- Arm 4: 4 x FlublokTreatment being tested
Flublok four times annually
Treatment: Placebo nasal spray and recombinant hemagglutinin influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study - a Randomized Controlled Trial
- Record updated
- 15 May 2026